Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors

NCT00259818 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Erimos Pharmaceuticals